Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alessandra Fabi

Showing results (131-140 of 265) with videos related to

Pageof 27
Sort By:
Chest|December 15, 2006
Is recurrent venous thromboembolism after therapy reduced by low-molecular-weight heparin compared with oral anticoagulants?Gianluigi Ferretti, Emilio Bria, Diana Giannarelli, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 11, 2011
HER2 protein and gene variation between primary and metastatic breast cancer: significance and impact on patient careAlessandra Fabi, Anna Di Benedetto, Giulio Metro, et al.
Journal of Experimental & Clinical Cancer Research : CR|May 17, 2011
Magnitude of risks and benefits of the addition of bevacizumab to chemotherapy for advanced breast cancer patients: Meta-regression analysis of randomized trialsFederica Cuppone, Emilio Bria, Vanja Vaccaro, et al.
Current Problems in Cancer|May 26, 2019
The unmet need for oncofertility preservation in women: Results of a survey by different oncological specialists in Lazio, ItalyAlessandra Fabi, Gaetano Lanzetta, Enrico Vizza, et al.
Cancer|August 10, 2005
New aromatase inhibitors as second-line endocrine therapy in postmenopausal patients with metastatic breast carcinoma: a pooled analysis of the randomized trialsPaolo Carlini, Emilio Bria, Diana Giannarelli, et al.
Neuro-Oncology|March 9, 2016
AVAREG: a phase II, randomized, noncomparative study of fotemustine or bevacizumab for patients with recurrent glioblastomaAlba A Brandes, Gaetano Finocchiaro, Vittorina Zagonel, et al.
The Oncologist|May 14, 2025
Delphi consensus on the management of adverse events in patients with metastatic triple-negative breast cancer treated with sacituzumab govitecanAnna Amela Valsecchi, Simona Pisegna, Andrea Antonuzzo, et al.
Oncology|August 10, 2005
Zoledronic-acid-induced circulating level modifications of angiogenic factors, metalloproteinases and proinflammatory cytokines in metastatic breast cancer patientsGianluigi Ferretti, Alessandra Fabi, Paolo Carlini, et al.
Therapeutic Advances in Medical Oncology|June 7, 2023
Adjuvant denosumab in early breast cancer: a systematic review and meta-analysis of randomized controlled clinical trialsLuca Mastrantoni, Giovanna Garufi, Elena Di Monte, et al.
Oncotarget|September 15, 2017
Early tumour shrinkage as a survival predictor in patients with recurrent glioblastoma treated with bevacizumab in the AVAREG randomized phase II studyAlba A Brandes, Gaetano Finocchiaro, Vittorina Zagonel, et al.
Pageof 27

Showing results (131-140 of 265) with videos related to

Sort By:
Pageof 27
Chest|December 15, 2006
Is recurrent venous thromboembolism after therapy reduced by low-molecular-weight heparin compared with oral anticoagulants?Gianluigi Ferretti, Emilio Bria, Diana Giannarelli, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 11, 2011
HER2 protein and gene variation between primary and metastatic breast cancer: significance and impact on patient careAlessandra Fabi, Anna Di Benedetto, Giulio Metro, et al.
Journal of Experimental & Clinical Cancer Research : CR|May 17, 2011
Magnitude of risks and benefits of the addition of bevacizumab to chemotherapy for advanced breast cancer patients: Meta-regression analysis of randomized trialsFederica Cuppone, Emilio Bria, Vanja Vaccaro, et al.
Current Problems in Cancer|May 26, 2019
The unmet need for oncofertility preservation in women: Results of a survey by different oncological specialists in Lazio, ItalyAlessandra Fabi, Gaetano Lanzetta, Enrico Vizza, et al.
Cancer|August 10, 2005
New aromatase inhibitors as second-line endocrine therapy in postmenopausal patients with metastatic breast carcinoma: a pooled analysis of the randomized trialsPaolo Carlini, Emilio Bria, Diana Giannarelli, et al.
Neuro-Oncology|March 9, 2016
AVAREG: a phase II, randomized, noncomparative study of fotemustine or bevacizumab for patients with recurrent glioblastomaAlba A Brandes, Gaetano Finocchiaro, Vittorina Zagonel, et al.
The Oncologist|May 14, 2025
Delphi consensus on the management of adverse events in patients with metastatic triple-negative breast cancer treated with sacituzumab govitecanAnna Amela Valsecchi, Simona Pisegna, Andrea Antonuzzo, et al.
Oncology|August 10, 2005
Zoledronic-acid-induced circulating level modifications of angiogenic factors, metalloproteinases and proinflammatory cytokines in metastatic breast cancer patientsGianluigi Ferretti, Alessandra Fabi, Paolo Carlini, et al.
Therapeutic Advances in Medical Oncology|June 7, 2023
Adjuvant denosumab in early breast cancer: a systematic review and meta-analysis of randomized controlled clinical trialsLuca Mastrantoni, Giovanna Garufi, Elena Di Monte, et al.
Oncotarget|September 15, 2017
Early tumour shrinkage as a survival predictor in patients with recurrent glioblastoma treated with bevacizumab in the AVAREG randomized phase II studyAlba A Brandes, Gaetano Finocchiaro, Vittorina Zagonel, et al.
Pageof 27